Ticagrelor for the treatment of acute coronary syndromes

  • Technology appraisal guidance
  • TA236
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the Liverpool Reviews and Implementation Group (LRiG):

  • Bagust A, Boland A, Blundell M et al. Ticagrelor for the treatment of acute coronary syndromes, February 2011

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors and professional or specialist and patient or carer groups also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • AstraZeneca

Professional or specialist, and patient or carer groups:

  • Action Heart

  • British Cardiovascular Intervention Society (BCIS)

  • British Cardiovascular Society

  • British Heart Foundation

  • Heart Care Partnership (UK)

  • HEART UK

  • Royal College of Nursing

  • Royal College of Physicians

  • South Asian Health Foundation

Other consultees:

  • Department of Health

  • NHS Bradford and Airedale

  • Oxfordshire PCT

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Bristol–Myers Squibb

  • British National Formulary

  • British Society for Cardiovascular Research

  • Commissioning Support Appraisals Service

  • Daiichi Sankyo

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Eli Lilly

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency (MHRA)

  • Sanofi–Aventis

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on ticagrelor by attending the initial Committee discussion and providing written evidence to the Committee. They are invited to comment on the ACD.

  • Nick Curzen, nominated by the Royal College of Physicians – clinical specialist

  • Professor Anthony Gershlick, Consultant Cardiologist, University Hospitals of Leicester, nominated by the Royal College of Physicians, Consultant Cardiologist, Southampton University Hospitals – clinical specialist

  • Liz Clark, nominated by the Heart Care Partnership – patient expert

  • John Miller, nominated by the Heart Care Partnership – patient expert

The following individuals were nominated as NHS Commissioning experts by the selected PCT allocated to this appraisal. They gave their expert and NHS commissioning personal view on ticagrelor by attending the initial Committee discussion and providing written evidence to the Committee. They are invited to comment on the ACD.

  • Greg Fell, Consultant in Public Health, NHS Bradford and Airedale selected by NHS Bradford and Airedale – NHS Commissioning expert

Representatives from the following manufacturer or sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • AstraZeneca